Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ProShares Ultra Semiconductors (USD) vs Zoetis Inc (ZTS) Price & Performance

ProShares Ultra SemiconductorsTrade
Zoetis IncTrade

Price performance (Past 24H)

Key statistics

ProShares Ultra Semiconductors vs Zoetis Inc — how do they compare? ProShares Ultra Semiconductors trades at $98.7 (market cap $2.94B), while Zoetis Inc trades at $73.24 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 10.3× ProShares Ultra Semiconductors's market cap, and Zoetis Inc pays a 2.9% dividend while ProShares Ultra Semiconductors pays none. Which is the better fit depends on your goals — on Pluang, investors hold ProShares Ultra Semiconductors for 29 Days and Zoetis Inc for 70 Days on average.

USDZTS
Market Cap
$2.94B$30.20B
Volume
630,1486,175,327
Sector
Leveraged / InverseHealth
52-Week High
$113.53$147.53
52-Week Low
$43.19$69.09
Typical Hold Time
29 Days70 Days
Enterprise Value
—$37.76B
Dividend Yield
—2.9%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ProShares Ultra Semiconductors

USD stock trades at $102.77, down 0.96% on the day, with a bullish technical signal driven by strong moving average alignment. The stock shows overbought conditions on shorter-term RSI readings while maintaining positive momentum indicators. Recent corporate actions include a scheduled dividend payment of $0.13 per share for September 2026. Price levels indicate support near $100-$102 and resistance at $103-$105.

The stock's technical strength contrasts with limited fundamental data availability. Investors face uncertainty regarding valuation metrics and profitability measures, requiring careful assessment of upcoming financial disclosures. Near-term price action will likely hinge on market sentiment and technical levels given the current information gap on core business fundamentals.

Zoetis Inc

Zoetis (ZTS) trades at $71.55, showing modest daily gains of 0.32% amid a challenging market environment. The stock faces bearish technical signals with mixed quarterly earnings performance - beating expectations in Q2 2026 but missing in Q1. Strong fundamentals persist with 71.67% gross margins and 27.69% net income margins, though recent headwinds include U.S. companion animal market weakness and increased competition in key therapeutic areas. The company maintains robust cash flow generation with $2.9 billion from operations in 2025.

Despite near-term pressures, ZTS presents value opportunity with attractive valuation at 11.67 P/E ratio and consensus price target of $87.33 suggesting 22% upside. Risks include ongoing competitive pressures and U.S. market softness, but industry-leading profitability and international growth provide stability. Analyst sentiment remains positive with no sell ratings among 32 covering firms, though technical indicators suggest cautious near-term positioning.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

USD
78% Buy22% Sell
Avg holding period · 29 Days
ZTS

No sentiment data available yet.

Top news

Latest headlines on both assets

About ProShares Ultra Semiconductors

USD is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Dow Jones U.S. Semiconductors™ Index. It is a tactical instrument designed for sophisticated traders looking to magnify short-term bullish views on the U.S. semiconductor industry, specifically focusing on large-cap leaders in the chip and equipment space.

Read more on USD →

About Zoetis Inc

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Read more on ZTS →